Bexley Dermatology Research

What Bexley Dermatology Research does

Bexley Dermatology Research (BDR) is a private, single-site clinical research organization headquartered in Bexley, Ohio, operating under the DOCS Dermatology Group umbrella. Founded in 2016 with seven employees, BDR conducts Phase 3 dermatology clinical trials for adult and adolescent patients across eight indications: plaque psoriasis, hidradenitis suppurativa, chronic spontaneous and chronic inducible urticaria, nonsegmental vitiligo, atopic dermatitis, alopecia areata, and warts. Active sponsor studies include TAK-279 (Takeda), lutikizumab, ritlecitinib (Pfizer), barzolvolimab (Sanofi), amlitelimab, baricitinib (Lilly), and EVO756. The site is led by Dr. Matthew Zirwas, ranked #9 on Newsweek's America's Best Dermatologists 2023 with 180+ peer-reviewed publications, supported by a board-certified sub-investigator, a physician assistant, a clinical operations manager with six years of tenure, and research coordinators. BDR generates revenue through professional-services contracts with pharmaceutical companies and CROs, paid per enrolled subject and study milestone; patients participate at no cost. Patient acquisition is driven by direct outreach (phone, online inquiry), healthcare-provider referrals via a formal referral form, and ClinicalTrials.gov listings, with brand reinforcement through Instagram, Facebook, YouTube, and the Derms on Drugs podcast produced with Scholars in Medicine. Operating scope is regional (Central Ohio), though the principal investigator and podcast give it national visibility within the dermatology community.

Name

Bexley Dermatology Research

Legal name

Bexley Dermatology Research

Website

https://bexleydermresearch.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Bexley Dermatology Research is a private, DOCS-affiliated clinical research site in Central Ohio conducting Phase 3 dermatology trials across psoriasis, HS, urticaria, vitiligo, atopic dermatitis, alopecia areata, and warts for pharma sponsors, led by Dr. Matthew Zirwas.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical Laboratories (621511)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

General & Medical Dermatology (HLAKACAA)

akta.pro secondary industries

Psoriasis & Eczema Specialty Care (HLAKACAL), Pigmentary Disorders (Vitiligo/Melasma) (HLAKACAM), Contact Dermatitis & Patch Testing (HLAKACAK)

Keywords

• Clinical trial management
• Dermatology research
• Clinical research site
• Phase 3 trials
• Dermatological drug trials

Headquarters

HQ city

Bexley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Contracts: Revenue generated through contracts with pharmaceutical companies and clinical research organizations conducting dermatological drug trials. The site serves as a clinical trial facility, receiving compensation for enrolling and managing study participants.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Bexley Dermatology Research is a clinical research site that recruits, screens, and manages study participants for Phase 3 dermatology clinical trials sponsored by pharmaceutical companies and CROs. It concurrently enrolls patients across multiple dermatological indications (psoriasis, hidradenitis suppurativa, vitiligo, chronic spontaneous urticaria, chronic inducible urticaria, atopic dermatitis, alopecia areata, and warts) and coordinates patient visits, dosing, safety monitoring, and data collection under standardized protocols. The site is affiliated with DOCS Dermatology Group, is led by Dr. Matthew Zirwas, and also accepts referrals from community dermatologists for trial enrollment.

Product overview

Bexley Dermatology Research operates as a dermatology clinical research site offering a unified platform of clinical trial services. The company conducts Phase 3 clinical trials across multiple dermatological conditions including psoriasis, hidradenitis suppurativa, chronic spontaneous and inducible urticaria, nonsegmental vitiligo, atopic dermatitis, alopecia areata, and warts. These trials are conducted as oral or injection therapies under standardized protocols. Supporting services include provider referral management, patient screening and coordination, and the Derms on Drugs educational podcast produced in partnership with Scholars in Medicine. The research site is affiliated with DOCS Dermatology Group and serves Central Ohio.

Differentiator

Problem solved

Functional benefit

Products and services

• Psoriasis Clinical Trials Phase 3 clinical trials for moderate-to-severe plaque psoriasis evaluating oral therapies such as TAK-279 for long-term safety, tolerability, and efficacy; conducted for pharmaceutical sponsors and CROs with patient enrollment and protocol execution at the Bexley site.
• Hidradenitis Suppurativa Clinical Trials Clinical trials for hidradenitis suppurativa in adult and adolescent subjects with moderate to severe disease, evaluating treatments such as lutikizumab; provided as a contract service to pharmaceutical sponsors.
• Chronic Spontaneous Urticaria Clinical Trials Phase 3 randomized, double-blind, placebo-controlled studies evaluating barzolvolimab for patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment; conducted under contract with the trial sponsor.
• Nonsegmental Vitiligo Clinical Trials A 104-week study (Tranquillo 2) evaluating ritlecitinib oral capsules for adults with nonsegmental vitiligo in both active and stable phases; delivered as a contract clinical research service.
• Chronic Inducible Urticaria Clinical Trials Studies evaluating the safety, tolerability, and efficacy of EVO756 in adults with chronic inducible urticaria; provided as a contract site service to the trial sponsor.
• Atopic Dermatitis Clinical Trials Open-label, long-term studies (ATLANTIS) evaluating subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis, including adolescent-only trials; delivered as a sponsor-contracted clinical research service.
• Alopecia Areata Clinical Trials Studies of baricitinib in children aged 6 years to less than 18 years with alopecia areata (BRAVE-AA-PEDS), adolescents only; conducted as a contract clinical trial site for the sponsor.
• Wart Treatment Clinical Trial Clinical trial service specifically for the evaluation of wart treatments at the Bexley research site, conducted under contract with the sponsoring organization.
• Provider Referral Services Clinical research coordination service enabling healthcare providers to refer patients for dermatology clinical trials via a Provider Referral Form, with patients returned to the referring provider after trial completion for continuity of care.
• Subject Participation Services Service for individuals interested in participating in clinical research, including screening visits, baseline visits, follow-up appointments, and connection to appropriate trials based on eligibility; provided free of charge to participants.
• Derms on Drugs Podcast Weekly podcast hosted by dermatologists Matt Zirwas, Laura Ferris, and Tim Patton discussing cutting-edge dermatology topics; produced by Scholars in Medicine and distributed via Spotify and Apple Podcasts for healthcare professionals.

Quantifiable outcome

• Premier dermatology research site in Central Ohio

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and minor.

• DOCS Dermatology GroupcoreStrategic or Co-development PartnerBexley Dermatology Research is affiliated with DOCS Dermatology Group. The partnership provides operational support, referral pathways for patients completing trials, and access to the broader dermatology clinic network. The group's Notice of Privacy Practices governs patient data handling.
• Scholars in MedicineminorGTM or Marketing PartnerScholars in Medicine is an online educational platform exclusively for healthcare professionals. They produce the Derms on Drugs podcast featuring Dr. Matthew Zirwas, providing educational content and extending BDR's reach to the medical community.

Scale indicators3 records

Recent moves1 record

Expansion highlights4 records

Broad incumbents

• Wake Research: Multi-site clinical research network running dermatology trials among other therapeutic areas. Overlaps with BDR on dermatology protocol execution but operates at much greater scale and geographic reach.
• Javara Research: Site-management organization embedding research within established medical practices. Comparable business model to BDR's DOCS-affiliated operations, but operates at network scale across multiple specialties.
• IQVIA (Dermatology Site Network): Global CRO with dedicated dermatology site networks and trial delivery capabilities. Competes with BDR for protocol placement at the sponsor level, though at vastly greater scale.
• Cetero Research: Early-phase clinical research organization with dermatology capabilities. Overlaps with BDR in dermatology clinical trial execution, though skewed toward Phase 1 and bioequivalence work.

Regional players

• DOCS Dermatology Group: Parent-affiliated dermatology clinic network providing operational and referral infrastructure to BDR. Comparable in that they operate as a Central Ohio dermatology practice with research exposure, but operates broader general dermatology rather than as a dedicated research site.

Direct peers

• Atlanta Center for Clinical Research: Dedicated outpatient clinical research site conducting multi-specialty trials including dermatology. Direct comparator in site-based trial execution, sponsor relationships, and patient-recruitment channels.
• ClinDatrix Inc. Dermatology-focused clinical research organization running Phase 2-4 trials across indications like psoriasis, atopic dermatitis, and acne. Closely mirrors BDR's indication mix and Phase-stage focus.
• ProCare Family Dermatology Research: Independent practice-based dermatology research site enrolling patients into industry-sponsored trials. Highly comparable operating model to BDR with similar sponsor-paid professional services revenue structure.
• DermResearchCenter of New York: Independent dermatology-focused clinical research site enrolling Phase 2-4 trials across multiple indications. Highly comparable to BDR in operating model, indication mix, and patient-recruitment approach, but based in the Northeast rather than Central Ohio.

Emerging players

• University Hospitals Cleveland — Dermatology Clinical Trials: Academic medical center dermatology trial program in Northeast Ohio. Comparable in indication mix and Phase 3 dermatology enrollment, but operates under academic-mission economics rather than independent-site economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCyunfJ6e1eaDCvz22JO-AkA
• Facebookfacebook.com/BexleyDermatologyResearch
• Instagraminstagram.com/bexleydermresearch
• LinkedInlinkedin.com/company/bexley-dermatology-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bexley Dermatology Research